Table 1.

Patient characteristics

Characteristic
Male sex – N (%)	13 (21)
Age at diagnosis in years – Median (range)	58 (26-78)
Smoking Status
Former/Current	12 (20)
Never (<100 cigarettes lifetime)	49 (80)
EGFR mutation – N (%)
Exon 19 deletion	41 (67)
Exon 18 E709A and G719A	1 (2)
Exon 21 L858R	19 (31)
Time on gefitinib or erlotinib (months)
Median (range)	19 (7-78)
Age at enrollment in years – Median (range)	61 (27-80)
Karnofsky Performance Status at enrollment (%)
90%	13 (21)
80%	37 (61)
70%	11 (18)
Lines of therapy prior to gefitinib/erlotinib (N%)
0	37 (61)
1	20 (32)
2	4 (7)
Lines of therapy after acquired resistance
0	41 (67)
1	12 (20)
2+	8 (13)
First-line gefitinib/erlotinib – N (%)
Single-agent	29 (48)
With chemotherapy	8 (13)
Maintenance after chemo	5 (9)
Gefitinib/erlotinib/Both – N (%)
Erlotinib	50 (82)
Gefitinib	6 (10)
Gefitinib followed by erlotinib	5 (8)
Acquired resistance to trial enrollment (months)
Median (range)	6 (0-48)